()
 
 

Overview

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE - News) is a biotechnology company engaged in developing breakthrough regenerative therapeutics to treat traumatic injuries and degenerative diseases. The Company maintains a world- class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin®, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular ...


Contact Information

85 Main Street
Hopkinton, MA 01748

tel: 508-497-2360
fax: 508-497-9964
http://www.alseres.com

,  



Investor Relations



tel:
fax:




Stock

Exchange: NASDAQ
Industry: Biotechnology
Market Cap: $50.7M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.